<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2008-491</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Фармакокинетика калиевой соли диклофенака после перорального приема саше и таблеток</article-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Martso</surname><given-names>A</given-names></name><name name-style="western" xml:lang="en"><surname>Martso</surname><given-names>A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Bo</surname><given-names>L D</given-names></name><name name-style="western" xml:lang="en"><surname>Bo</surname><given-names>L D</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Verga</surname><given-names>F</given-names></name><name name-style="western" xml:lang="en"><surname>Verga</surname><given-names>F</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Monti</surname><given-names>N Ts</given-names></name><name name-style="western" xml:lang="en"><surname>Monti</surname><given-names>N Ts</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Abbondati</surname><given-names>G</given-names></name><name name-style="western" xml:lang="en"><surname>Abbondati</surname><given-names>G</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Tettamanti</surname><given-names>R A</given-names></name><name name-style="western" xml:lang="en"><surname>Tettamanti</surname><given-names>R A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Krivelli</surname><given-names>F</given-names></name><name name-style="western" xml:lang="en"><surname>Krivelli</surname><given-names>F</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ur</surname><given-names>M R</given-names></name><name name-style="western" xml:lang="en"><surname>Ur</surname><given-names>M R</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ismaili</surname><given-names>Sh</given-names></name><name name-style="western" xml:lang="en"><surname>Ismaili</surname><given-names>Sh</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Marzo</surname><given-names>A</given-names></name><name name-style="western" xml:lang="en"><surname>Marzo</surname><given-names>A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Bo</surname><given-names>L D</given-names></name><name name-style="western" xml:lang="en"><surname>Bo</surname><given-names>L D</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Verga</surname><given-names>F</given-names></name><name name-style="western" xml:lang="en"><surname>Verga</surname><given-names>F</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Monti</surname><given-names>H Z</given-names></name><name name-style="western" xml:lang="en"><surname>Monti</surname><given-names>H Z</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Abbondati</surname><given-names>G</given-names></name><name name-style="western" xml:lang="en"><surname>Abbondati</surname><given-names>G</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Tettamanti</surname><given-names>R A</given-names></name><name name-style="western" xml:lang="en"><surname>Tettamanti</surname><given-names>R A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Crivelli</surname><given-names>F</given-names></name><name name-style="western" xml:lang="en"><surname>Crivelli</surname><given-names>F</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ur</surname><given-names>M R</given-names></name><name name-style="western" xml:lang="en"><surname>Ur</surname><given-names>M R</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ismaili</surname><given-names>Sh</given-names></name><name name-style="western" xml:lang="en"><surname>Ismaili</surname><given-names>Sh</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>25</day><month>09</month><year>2008</year></pub-date><volume>2</volume><issue>3</issue><issue-title>№3 (2008)</issue-title><fpage>59</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Martso A., Bo L.D., Verga F., Monti N.T., Abbondati G., Tettamanti R.A., Krivelli F., Ur M.R., Ismaili S., Marzo A., Bo L.D., Verga F., Monti H.Z., Abbondati G., Tettamanti R.A., Crivelli F., Ur M.R., Ismaili S., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Martso A., Bo L.D., Verga F., Monti N.T., Abbondati G., Tettamanti R.A., Krivelli F., Ur M.R., Ismaili S., Marzo A., Bo L.D., Verga F., Monti H.Z., Abbondati G., Tettamanti R.A., Crivelli F., Ur M.R., Ismaili S.</copyright-holder><copyright-holder xml:lang="en">Martso A., Bo L.D., Verga F., Monti N.T., Abbondati G., Tettamanti R.A., Krivelli F., Ur M.R., Ismaili S., Marzo A., Bo L.D., Verga F., Monti H.Z., Abbondati G., Tettamanti R.A., Crivelli F., Ur M.R., Ismaili S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/176">https://mrj.ima-press.net/mrj/article/view/176</self-uri><abstract><p>Существует множество фармацевтических форм диклофенака, благодаря чему его можно применять перорально, ректально, внутримышечно или местно.
Цель исследования - сравнительный анализ фармакокинетических показателей и изменений во времени сывороточной концентрации калиевой соли диклофенака после перорального приема в дозе 50 мг в форме саше или таблеток, покрытых сахарной оболочкой. Результаты исследования. Доказано, что и саше, и таблетки обследованные переносили одинаково хорошо, о чем свидетельствовали субъективные и объективные наблюдения. Выраженные побочные эффекты отсутствовали, а в лабораторных анализах и показателях жизненно важньх функций не отмечалось существенных изменений. Калиевая соль диклофенака в форме таблеток с немедленным высвобождением (50 и 100мг) оказывает очень хорошее обезболивающее действие при лечении мигрени, поскольку концентрация препарата в плазме крови достигала максимальной в среднем через 1 ч после приема (через 0,33-2 ч), а анальгезирующий эффект развивался через 60-90мин. Заключение. Сравнивая скорость всасывания, можно заключить, что диклофенак калия в форме саше будет давать гораздо более быстрый обезболивающий эффект. Таким образом, высокая растворимость калиевой соли диклофенака и очень хорошая всасываемость (особенно саше) делают препарат превосходным анальгетиком, оказывающим быстрое обезболивающее действие.</p></abstract><trans-abstract xml:lang="en"><p>There is a host of pharmaceutical formulations of diclofenac, which ensures that it can be used orally, rectally, intrarectally, or topically. Objective - to comparatively analyze the pharmacokinetic parameters and time course of changes in the serum concentration of diclofenac potassium after oral administration in a dose of 50 mg as sachets or sugar-coated tablets.
Results. There is evidence that patients tolerate both its sachets and tablets equally well, as confirmed by subjective and objective observations. There are neither marked side effects nor considerable changes in laboratory tests and in the values of vital functions. Diclofenac potassium as early-action tablets (50 and 100 mg) exerts a very good analgesic effect in treating migraine since the plasma concentration of the drug peaks on an average of an hour of administration (range 0,33-2 hours) and the analgesic effect developed following 60-90 min. Conclusion. By comparing the rate of absorption, it may be concluded that diclofenac potassium as sachets will produce a much rapider analgesic effect. Thus, the high solubility of diclofenac potassium and its very good absorbability (as sachets in particular) make the drug a superior analgesic that has a rapid analgesic activity.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Martindale - The Extra Pharmacopoeia 31 st Ed., p. 36-37. The Royal Pharmaceutical Society, London, 1996.&lt;/p&gt;&lt;p&gt;Todd P.A., Sorkin E.M. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmaco-kinetic properties and therapeutic efficacy. Drugs 35, 244 regulations for continuing clinical trials. Pharmacol Res 1998; 37: 321.&lt;/p&gt;&lt;p&gt;Shah V.P., Midha K.K., Dighe S. et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992; 81: 309.&lt;/p&gt;&lt;p&gt;Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259.&lt;/p&gt;&lt;p&gt;Marzo A., Ceppi Monti N. Acceptable and unacceptable procedures in bioavailability and bioequiva- lence trials. Pharmacol Res 1998; 38: 401.&lt;/p&gt;&lt;p&gt;Anonymous. CPMP. Note for guidance on the investigation of bioavailability and bioequiva-lence. CPMP / EWP / QWP / 1401 /98 draft. December 1998. 7&lt;/p&gt;&lt;p&gt;Anonymous. In vivo Bioequivalence Guidances/General Information. United States Pharmacopoeia 1998; 23: (suppl. 8): 4382.&lt;/p&gt;&lt;p&gt;Schuimann D. 1, A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657.&lt;/p&gt;&lt;p&gt;Riess W., Stierlin H., Degen P. et al. Pharmacokinetics and metabolism of the anli-inflammatory agent voltaren. Scand J Rheumatol 1978; (suppl. 22): 17.&lt;/p&gt;&lt;p&gt;Derendorf H., Mullersman G., Bart J. et al. Pharmacokinetics diclofenac sodium after intramuscular administration in combination with triamci-nolone acetate. Eur J Clin Pharmacol 1986; 31: 263.&lt;/p&gt;&lt;p&gt;Davies H.M., Anderson K.E. Clinical phutnia-cokinetic of diclofenac. Therapeutic insights and pitfalls Clin Pharmacokinet 1997; 33: 184.&lt;/p&gt;&lt;p&gt;McNeely W., Goa K.L. Diclofenac-potassium in migraine. A review Drugs 1999; 57: 991.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Martindale - The Extra Pharmacopoeia 31 st Ed., p. 36-37. The Royal Pharmaceutical Society, London, 1996.&lt;/p&gt;&lt;p&gt;Todd P.A., Sorkin E.M. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmaco-kinetic properties and therapeutic efficacy. Drugs 35, 244 regulations for continuing clinical trials. Pharmacol Res 1998; 37: 321.&lt;/p&gt;&lt;p&gt;Shah V.P., Midha K.K., Dighe S. et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992; 81: 309.&lt;/p&gt;&lt;p&gt;Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259.&lt;/p&gt;&lt;p&gt;Marzo A., Ceppi Monti N. Acceptable and unacceptable procedures in bioavailability and bioequiva- lence trials. Pharmacol Res 1998; 38: 401.&lt;/p&gt;&lt;p&gt;Anonymous. CPMP. Note for guidance on the investigation of bioavailability and bioequiva-lence. CPMP / EWP / QWP / 1401 /98 draft. December 1998. 7&lt;/p&gt;&lt;p&gt;Anonymous. In vivo Bioequivalence Guidances/General Information. United States Pharmacopoeia 1998; 23: (suppl. 8): 4382.&lt;/p&gt;&lt;p&gt;Schuimann D. 1, A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657.&lt;/p&gt;&lt;p&gt;Riess W., Stierlin H., Degen P. et al. Pharmacokinetics and metabolism of the anli-inflammatory agent voltaren. Scand J Rheumatol 1978; (suppl. 22): 17.&lt;/p&gt;&lt;p&gt;Derendorf H., Mullersman G., Bart J. et al. Pharmacokinetics diclofenac sodium after intramuscular administration in combination with triamci-nolone acetate. Eur J Clin Pharmacol 1986; 31: 263.&lt;/p&gt;&lt;p&gt;Davies H.M., Anderson K.E. Clinical phutnia-cokinetic of diclofenac. Therapeutic insights and pitfalls Clin Pharmacokinet 1997; 33: 184.&lt;/p&gt;&lt;p&gt;McNeely W., Goa K.L. Diclofenac-potassium in migraine. A review Drugs 1999; 57: 991.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
